Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00654706 · ClinicalTrials.gov registry record · Phase 3
Efficacy Study Exploring the Effects on Cognition of Sertindole Versus Comparator in Patients With Schizophrenia
A Phase 3 study, sponsored by H. Lundbeck A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 264
- Enrollment target
NCT00654706 is a Phase 3 study that has completed, run by H. Lundbeck A/S. The registered enrollment target is 264 participants.
The verdict
NCT00654706, a Phase 3 study, has completed, sponsored by H. Lundbeck A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 264 participants
- Enrollment target
Study Summary
The objective of this study is to explore the neurocognitive efficacy of Sertindole versus comparator in patients with schizophrenia using the MCCB.
Interventions
- DRUG Quetiapine
- DRUG Sertindole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 264 participants |
| Start Date | 2008-03 |
| Est. Completion | 2010-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00654706
The ClinicalTrials.gov registry entry for NCT00654706 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 264 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lundbeck A/S, which has 72 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Quetiapine is the first listed.
NCT00654706 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00654706 about?
NCT00654706 is a clinical study titled "Efficacy Study Exploring the Effects on Cognition of Sertindole Versus Comparator in Patients With Schizophrenia". The objective of this study is to explore the neurocognitive efficacy of Sertindole versus comparator in patients with schizophrenia using the MCCB.
What is the current status of trial NCT00654706?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 264 participants. The study started on 2008-03. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00654706?
The interventions under investigation include: Quetiapine (DRUG), Sertindole (DRUG).
Who is sponsoring clinical trial NCT00654706?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.